Use of standard triple therapy in the treatment of Helicobacter pylori infection in adult

Aim. Compare the efficacy of Helicobacter pylori eradication and tolerance of 10-day and 7-day standard triple therapy of H. pylori infection in adults. Materials and methods. In total, 136 H. pylori-infected subjects participated in the randomized clinical trial. 68 patients of the first group received a 10-day standard triple therapy: esomeprazole (20 mg 2 times a day), clarithromycin (500 mg 2 times a day) and amoxicillin (1000 mg 2 times a day). 68 patients of the second group - 7-day standard triple therapy: esomeprazole (20 mg 2 times a day), clarithromycin (500 mg 2 times a day) and amoxicillin (1000 mg 2 times a day). H. pylori stool antigen was performed to check for eradication. Results. The efficacy of H. pylori eradication, according to ITT-analysis, in patients of the first and second groups was 82.4% and 64.7% (p=0.020), and according to PP-analysis - 87.5% and 66.7% (p=0.010). Adverse events were reported in 25% of the first group and 36.8% of patients in the second group. There were no statistically significant differences of adverse events in both groups (p>0.05). Conclusion. 10-day standard triple therapy appears to be more effective than 7-day without increasing frequent adverse events. It is not recommended to use 7-day standard triple therapy in the treatment of H. pylori infection in adults in the Smolensk region due to the low frequency eradication of H. pylori. The use of a 10-day standard triple therapy has extremely acceptable efficacy and can be recommended as a therapy for the first line of H. pylori infection.

efficacy of H. pylori eradication, adverse events, standard triple therapy